I see a lot of similarity, with ACAD being a few months ahead in their move. I suspect we see a move to the next leg up around $15 very soon, and then make the next base. It has held nicely in the $2.10 pre split, $12.50 post split range, while maintaining high volume. This stock is gaining attention by big money by the day, and momentum should carry it into the mid teens very soon. Anyone have a price prediction leading into the news release at the E uropean conference in a couple months?
redleg, that is around $16.50, I tend to think a little higher, around $18. I think this current move will take it to a $15 basing area for a few weeks, then a run up to meeting to around $18. As for charts, after looking at them for years, I have come to be able to use them pretty for for buying signs.
I guess I would side with redleggi on the 'going into' part of the meeting. Afterwards....a GOOD meeting and mid 20's likely...a GREAT meeting and we're into the 30's and climbing. Our worry will be how soon Amgen makes the move to acquire CYTK as I'm sure they don't want to spend 'milestone' money when they can get more bang for the buck by acquiring it. Don't forget that 'intravenous' is being evaluated at the Sept meeting but 'oral' is the biggest moneymaker of the two. T is an absolute wildcard....
some good points , guys. Needless to say, about 8 this morning, I was sort of dazed. Appears common sense , and Big money prevailed. Got to know a lot of us little guys got stopped out Any one else see similarity to ACAD chart, or have thoughts on sp into the European meeting?.
I don't care about charts. Fundamentally, if cardiac trial is a success, FDA will NOT require phase III and will probably give the drug a breakthrough designation, at which point market cap should be about $1.5 bil or $55/share (or $50 assuming they will raise money at $25 or so).
Additional success in ALS would make it ~3 bil company or ~100-110/share.
ONYXX is 10 bil on 350 mil in revenue.